Impact of HER2 and PTEN Simultaneous Deregulation in Non-small Cell Lung Carcinoma: Correlation with Biological Behavior |
Panagiotou, Ioannis
(Department of Thoracic Surgery, 401 General Military Hospital)
Georgiannos, Stavros N. (Department of Breast Cancer Surgery, Blue Cross Hospital) Tsiambas, Evangelos (Department of Pathology, Medical School, University of Athens) Karameris, Andreas (Department of Pathology, 417 NIMTS Hospital) Konstantinou, Marios (2nd Thoracic Surgery Department, Sotiria Chest Diseases Hospital) Lazaris, Andreas C. (Department of Pathology, Medical School, University of Athens) Kavantzas, Nikolaos (Department of Pathology, Medical School, University of Athens) Vilaras, George (Department of Pathology, 417 NIMTS Hospital) Patsouris, Efstratios (Department of Pathology, Medical School, University of Athens) |
1 | O'Byrne KJ, Gatzemeier U, Bondarenko I, et al (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol, 12, 795-805. DOI ScienceOn |
2 | Olaussen KA, Soria JC, Mοrat L, et al (2003). Loss of PTEN expression is not uncommon but lacks prognostic value in stage I NSCLC. Anticancer Res, 23, 4885-90. |
3 | Pelosi G, Del CB, Dell'Orto P, et al (2005). Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer, 113, 101-8. DOI ScienceOn |
4 | Perez EA, Reinholz MM, Hillman DW, et al (2010). HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol, 28, 4307-15. DOI ScienceOn |
5 | Sher T, Dy GK, Adjei AA (2008). Small cell lung cancer. Mayo Clin Proc, 83, 355-67. DOI ScienceOn |
6 | Shoman N, Klassen S, McFadden A, et al (2005). Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol, 18, 250-9. DOI ScienceOn |
7 | Song MS, Salmena L, Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283-96. DOI ScienceOn |
8 | Swanton C, Futreal A, Eisen T (2006). Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res, 12, 4377-83. DOI ScienceOn |
9 | Takenaka M, Hanagiri T, Shinohara S, et al (2011). The prognostic significance of HER2 overexpression in nonsmall cell lung cancer. Anticancer Res, 31, 4631-6. |
10 | Marsit CJ, Zheng S, Aldape K, et al (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76. DOI ScienceOn |
11 | Meert AP, Martin B, Paesmans M, et al (2003). The role of HER- 2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer, 89, 959-65. DOI ScienceOn |
12 | Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). Non-Small Cell Lung Cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94. DOI |
13 | Nagata Y, Lan KH, Zhou X, et al (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-27. DOI ScienceOn |
14 | Nakamura H, Saji H, Ogata A, et al (2003). Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer, 103, 61-6. DOI ScienceOn |
15 | Au NH, Cheang M, Huntsman DG, et al (2004). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol, 204, 101-9. DOI ScienceOn |
16 | Bendell JC, Rodon J, Burris HA, et al (2012). Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol, 30, 282-90. DOI ScienceOn |
17 | Bepler G, Sharma S, Cantor A, et al (2004). RRM and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol, 22, 1878-85. DOI ScienceOn |
18 | Tan D, Deeb G, Wang J, et al (2003). HER2 protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol, 12, 201-11. DOI ScienceOn |
19 | Tang JM, He QY, Guo RX, et al (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51, 181-91. DOI ScienceOn |
20 | Timotheadou E, Skarlos DV, Samantas E, et al (2007). Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res, 27, 4481-9. |
21 | Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84. DOI ScienceOn |
22 | Vogel CL, Cobleigh MA, Tripathy D, et al (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20, 719-26. DOI ScienceOn |
23 | Wang L, Zhang Q, Zhang J, et al (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248. DOI |
24 | Wang L, Yue W, Zhang L, et al (2012). mTOR and PTEN expression in non-small cell lung cancer: analysis by realtime fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today, 42, 419-25. DOI ScienceOn |
25 | Cagle PT, Chirieac LR (2012). Advances in treatment of lung cancer targeted therapy. Arch Pathol Lab Med, 136, 504-9. DOI ScienceOn |
26 | Chu EC, Tarnawski AS (2004). PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit, 10, 235-41. |
27 | Yoo SB, Xu X, Lee HJ, et al (2011). Loss of PTEN expression is an independent poor prognostic factor in non-small cell lung cancer. Korean J Pathol, 45, 329-35. DOI |
28 | Citri A, Yarden Y (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 7, 505-16. DOI ScienceOn |
29 | Gatzemeier U, Groth G, Butts C, et al (2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol, 15, 19-27. DOI ScienceOn |
30 | Hirsch FR, Varella-Garcia M, Franklin WA, et al (2002). Evaluation of HER-2/neu gene amplification and protein expression in nonsmall cell lung carcinomas. Br J Cancer, 86, 1449-56. DOI ScienceOn |
31 | Jemal A, Bray F, Center M, et al (2011). Global Cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
32 | Jin G, Kim MJ, Jeon HS, et al (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 69, 279-83. DOI ScienceOn |
33 | Kang YH, Lee HS, Kim WH (2002). Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest, 82, 285-91. DOI ScienceOn |
34 | Lee SY, Kim MJ, Jin G, et al (2010). Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol, 5, 1734-40. DOI ScienceOn |
35 | Lim WT, Zhang WH, Miller CR, et al (2007). PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep, 17, 853-7. |
36 | Liu L, Shao X, Gao W, et al (2010). The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol, 5, 1922-32. DOI ScienceOn |
37 | Maira SM, Stauffer F, Schnell C, Garcia-Echeverrıa C (2009). PI3K inhibitors for cancer treatment: where do we stand. Biochem Soc Trans, 37, 265-72. DOI ScienceOn |